We take risks and challenge the status quo because disease must be fought with unexpected practice.
Unlike traditional therapeutic approaches that target growth factors in their active states, Scholar Rock uses its technology platform and structural insights to discover new medicines designed to selectively target the precursor, or inactive, forms of growth factors with the aim of avoiding toxicity and improving efficacy.Learn About Our Science
Scholar Rock works across therapeutic areas and shines new light on the overlooked to better target disease.
Our growing team is replete with good people who eat, sleep, and breathe good science. We promote a spirit of inquiry outside one’s traditional expertise to uncover enlightened solutions for patients.
Spinal Muscular Atrophy
In partnership with Gilead Sciences
September 23, 2021
Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress
September 22, 2021
Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference
August 16, 2021
Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer